ERCCI和P53预测Ⅱ期结肠癌FOLFOX方案辅助化疗获益的研究
2014-09-11彭杰文林贵南萧剑军
彭杰文+林贵南+萧剑军
[摘要] 目的 评价ERCCI和P53在Ⅱ期结肠癌中FOLFOX方案辅助化疗获益的预测作用。 方法 回顾性收集58例Ⅱ期结肠癌,均接受12疗程FOLFOX方案辅助化疗;利用免疫组化方法检测ERCC1和P53的表达水平,并评价它们的表达水平与无病生存期的关系。 结果 在58例患者中,ERCC1的表达率为62.1%,ERCC1阴性表达患者的中位DFS明显高于阳性表达者(6.2 vs 5.1 年,P=0.02);而P53的表达率为48.3%,P53阴性与阳性表达患者的中位DFS差异无统计学意义(5.3 vs 5.6年,P=0.93)。 结论 在Ⅱ期结肠癌中,ERCC1表达可能预测FOLFOX6辅助化疗的获益减少。
[关键词] ERCC1;P53;免疫组化;结肠癌;化疗
[中图分类号] R735.35 [文献标识码] A [文章编号] 2095-0616(2014)11-20-04
The predictive role of ERCC1 and P53 on benefit from FOLFOX adjuvant chemotherapy
PENG Jiewen LIN Guinan XIAO Jianjun
Department of Cancer Chemotherapy, Zhongshan City People's Hospital, Zhongshan 528400, China
[Abstract] Objective To evaluate the predictive role of ERCC1 and P53 on benefit from FOLFOX adjuvant chemotherapy. Methods 58 stageⅡcolon cancer patients receiving FOLFOX adjuvant chemotherapy were included. Testing the expression level of ERCC1 and P53 by immunohistochemistry method and assessing the association of expression level with disease-free survival(DFS). Results Among 58 patients, the rate of ERCC1 expression was 62.1%, and ERCC1-negative patients had significantly longer DFS than patients with ERCC1expression (6.2 vs 5.1 years, P=0.02). However, the rate of P53 expression was 48.3%, the DFS between P53-negative and positive patients was not of statistically significant difference(5.3 vs 5.6 years, P=0.93). Conclusion In patients with stageⅡcolon cancer, ERCC1 expression may predict less benefit from FOLFOX adjuvant chemotherapy.
[Key words] ERCC1; P53; Immu0histochemistry; Colon cancer; Chemotherapy
我国结肠癌的发病率逐年上升,随着结肠癌筛查的普及,早期结肠癌的比例不断增加[1]。单纯手术完全切除的Ⅱ期结肠癌约有25%患者在5年内出现复发[2]。术后辅助性化疗仍处于争议中。ASCO认为对于具有不良预后因素可考虑辅助性化疗,但长期无病生存的获益不超5%,而且化疗带来毒副反应[3]。因此,Ⅱ期结肠癌的个体化辅助化疗需要建立在有效的预测化疗获益的指标上,避免治疗过度或治疗不足。Yoshinori Shirota等[4]学者分析接受奥沙利铂及氟尿嘧啶化疗的晚期结直肠癌肿瘤组织ERCC1mRNA表达水平,认为肿瘤组织ERCC1mRNA的表达水平是预测接受奥沙利铂及氟尿嘧啶化疗的晚期结直肠癌生存的独立预测指标。A. Zaanan等[5]学者认为在Ⅲ期结肠癌中,p53表达的患者接受FOLFOX方案比接受FL方案获
得更高的3年无病生存。本实验研究ERCC1和P53在Ⅱ期结肠癌的表达情况以及在预测FOLFOX辅助化疗获益的作用。
1 资料与方法……p>
